Deargen

Deargen is an AI-first pharmatech company transforming the future of treating undruggable diseases through its AI platform called Dr.UG. The platform specializes in genome data analysis, biomarker prediction, AI-powered target discovery, molecule selection, and lead optimization for small molecule drug design. Dr.UG uses deep learning technology to discover new disease targets and realize precision medicine by designing small molecules for new drugs. Deargen's AI technology is being applied to various new drug development treatment strategies including PROTAC, ADC, epitope, agonist, and inhibitor approaches. The company has announced a patent application for a triple-negative breast cancer treatment and signed a joint research agreement with Samsung Medical Center. Founded in 2016 and headquartered in Seoul, South Korea, with offices in Daejeon and Suwanee, Georgia, Deargen has raised $17 million in Series B funding from investors including Nvester, The Wells Investment, Korean Development Bank, T S Investment, and Hana Ventures. The company also partners with Serengen for drug discovery acceleration and maintains corporate partnerships and scientific collaborations to advance its pipeline of AI-driven therapeutic candidates.